By Marilynn Larkin, MARCH 17, 2021
Dr. Alex Dimitriu founder of Menlo Park Psychiatry and Sleep Medicine in California also commented by email. “There appears to be improvement at six months, which is then lost at 12 months. Also, and perhaps suggestive of a placebo effect, for both adherent and non-adherent.” “While there may still be a relationship between SSD and inflammation, at least per this study it appears that simvastatin, via an ant-inflammatory or cholesterol lowering effect, does not change the course of the illness,” he said. “It is worth noting that while there was no benefit to illness severity, the metabolic benefits of statins including lowering cardiovascular morbidity are still impressive.”
Click HERE for the full article.